Acumen Pharmaceuticals (ABOS) 10-Q 16 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2022	May 13, 2022
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Entity Registrant Name	Acumen Pharmaceuticals, Inc.
Entity Central Index Key	0001576885
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-40551
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4108129
Entity Address, Address Line One	427 Park St.
Entity Address, City or Town	Charlottesville
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	22902
City Area Code	434
Local Phone Number	297-1000
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	ABOS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		40,501,258

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 108,764	$ 122,162
Marketable securities, short-term	80,326	72,075
Prepaid expenses and other current assets	3,008	4,424
Total current assets	192,098	198,661
Marketable securities, long-term	27,658	31,619
Property and equipment, net	51	36
Right-of-use asset	201
Other assets	79	14
Total assets	220,087	230,330
Current liabilities
Accounts payable	1,219	1,088
Accrued expenses and other current liabilities	2,578	4,059
Operating lease liability, current portion	139
Total current liabilities	3,936	5,147
Operating lease liability, net of current portion	62
Total liabilities	3,998	5,147
Commitments and contingencies (Note 9)
Stockholders' equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2022 and December 31, 2021
Common stock, $0.0001 par value; 300,000,000 shares authorized and 40,473,270 shares issued and outstanding as of March 31, 2022 and December 31, 2021	4	4
Additional paid-in capital	353,599	352,981
Accumulated deficit	(136,700)	(127,571)
Accumulated other comprehensive loss	(814)	(231)
Total stockholders' equity	216,089	225,183
Total liabilities and stockholders' equity	$ 220,087	$ 230,330

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par or stated value per share	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock Par Value	$ 0.0001	$ 0.0001
Common Shares Authorized	300,000,000	300,000,000
Common Shares Issued	40,473,270	40,473,270
Common Shares Outstanding	40,473,270	40,473,270

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses
Research and development	$ 5,985	$ 2,578
General and administrative	3,221	1,215
Total operating expenses	9,206	3,793
Loss from operations	(9,206)	(3,793)
Other income (expense)
Interest income, net	76	4
Change in fair value of preferred stock tranche rights liability and preferred stock warrant liability		(23,217)
Other income, net	1	9
Total other income (expense)	77	(23,204)
Net loss	(9,129)	(26,997)
Other comprehensive loss
Unrealized loss on marketable securities	(583)
Comprehensive loss	$ (9,712)	$ (26,997)
Net loss per common share, basic and diluted	$ (0.23)	$ (64.41)
Weighted-average shares outstanding, basic and diluted	40,473,270	419,124

Condensed Statements of Changes

Condensed Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Series A Convertible Preferred Stock [Member]	Series A-1 Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss
Opening balance at Dec. 31, 2020		$ 1,067	$ 16,333	$ 39,253
Opening balance at Dec. 31, 2020	$ (18,591)					$ 8,374	$ (26,965)
Opening balance (Shares) at Dec. 31, 2020		477,297	7,537,879	11,862,043	419,124
Share-based compensation	126					126
Net loss	(26,997)						(26,997)
Closing balance at Mar. 31, 2021		$ 1,067	$ 16,333	$ 39,253
Closing balance at Mar. 31, 2021	(45,462)					8,500	(53,962)
Closing balance (Shares) at Mar. 31, 2021		477,297	7,537,879	11,862,043	419,124
Opening balance at Dec. 31, 2021	225,183				$ 4	352,981	(127,571)	$ (231)
Opening balance (Shares) at Dec. 31, 2021					40,473,270
Unrealized loss on marketable securities	(583)							(583)
Share-based compensation	618					618
Net loss	(9,129)						(9,129)
Closing balance at Mar. 31, 2022	$ 216,089				$ 4	$ 353,599	$ (136,700)	$ (814)
Closing balance (Shares) at Mar. 31, 2022					40,473,270

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss	$ (9,129)	$ (26,997)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	4
Change in fair value of preferred stock tranche rights liability and preferred stock warrant liability		23,217
Stock-based compensation expense	618	126
Amortization of premiums and accretion of discounts on marketable securities, net	216
Amortization of right-of-use asset	33
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,416	(44)
Other assets	(65)	(13)
Accounts payable	121	387
Operating lease liability	(32)
Accrued expenses and other current liabilities	(1,481)	954
Net cash used in operating activities	(8,299)	(2,370)
Cash flows from investing activities
Purchases of marketable securities	(9,090)
Proceeds from maturities and sales of marketable securities	4,000
Purchases of property and equipment	(9)
Net cash used in investing activities	(5,099)
Net change in cash and cash equivalents	(13,398)	(2,370)
Cash and cash equivalents at the beginning of the period	122,162	43,777
Cash and cash equivalents at the end of the period	108,764	41,407
Supplemental disclosure of noncash investing and financing activities
Purchases of property and equipment in accounts payable	$ 10
Deferred offering costs in accrued expenses and other current liabilities		$ 257

Description of Organization and

Description of Organization and Business Operations	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Organization and Business Operations	NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Acumen Pharmaceuticals, Inc. (“Acumen” or the “Company”) was incorporated in 1996 in the state of Delaware. Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what the Company believes to be a key underlying cause of Alzheimer’s disease (“AD”). Acumen’s sole drug candidate, ACU193, is a humanized monoclonal antibody which selectively targets amyloid-beta oligomers. The Company is subject to the uncertainty of whether the Company’s intellectual property will develop into successful commercial products. June 2021 Reverse Stock Split The Company’s Board of Directors (“Board”) approved a reverse split of shares of the Company’s common stock and convertible preferred stock on a 1-for-1.49 basis (the “June 2021 Reverse Stock Split”), which was effected on June 23, 2021. The par value and the number of authorized shares of the convertible preferred stock and common stock were not adjusted in connection with the June 2021 Reverse Stock Split. All references to common stock, convertible preferred stock, warrants to purchase common stock, warrants to purchase convertible preferred stock, options to purchase common stock, share data, per share data and related information contained in the financial statements have been retrospectively adjusted to reflect the effect of the June 2021 Reverse Stock Split for all periods presented. No fractional shares of the Company’s common stock were issued in connection with the June 2021 Reverse Stock Split. Any fractional share resulting from the June 2021 Reverse Stock Split was rounded down to the nearest whole share, and any stockholder entitled to a fractional share as a result of the June 2021 Reverse Stock Split received a cash payment in lieu of receiving fractional shares. Initial Public Offering On July 6, 2021, the Company issued 9,999,999 shares of common stock in an initial public offering (“IPO”), and on July 8, 2021, the Company issued an additional 1,499,999 shares of common stock that were purchased by the underwriters pursuant to the underwriters’ option to purchase additional shares at the public offering price less underwriting discounts and commissions. The price to the public for each share was $16.00. The aggregate net proceeds from the Company’s IPO, after underwriting discounts and commissions and other offering expenses of $15.4 million, were $168.6 million. On July 6, 2021, in connection with the closing of the IPO, 477,297 shares of Series A, 7,985,305 shares of Series A-1, and 19,770,070 shares of Series B convertible preferred stock, respectively, automatically converted into an equal number of shares of common stock. Warrants to purchase shares of common stock were automatically net exercised for the purchase of an aggregate of 178,847 shares of common stock. As a result of the IPO, the underwriters’ exercise of their option, the conversions of the Series A, A-1 and B convertible preferred stock, and the exercise of the warrants, the Company’s total number of outstanding common shares increased by 39,911,517 immediately following the closing of the IPO. Liquidity and Capital Resources The Company has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of March 31, 2022 and December 31, 2021, the Company had an accumulated deficit of $136.7 million and $127.6 million, respectively, and working capital of $188.1 million and $193.5 million, respectively. Management believes that its existing financial resources are sufficient to continue operating activities at least through 2025. Future capital requirements will depend upon many factors, including the timing and extent of spending on research and development and market acceptance of the Company’s products. The Company may need to obtain additional financing to complete clinical trials and launch and commercialize any product candidates for which it receives regulatory approval. Until such time, if ever, the Company can generate revenue sufficient to achieve profitability, the Company expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. There can be no assurance that such financing will be available on terms acceptable to the Company, or at all. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation of other preferences that adversely affect the rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. The Company may be required to delay, limit, reduce or terminate its product discovery and development activities or future commercialization efforts. The Company initiated a Phase 1 clinical trial of ACU193 in 2021, which the Company named “INTERCEPT-AD.” In October 2021, the Company announced the initial dosing of the first patient in the INTERCEPT-AD (“COVID-19”) COVID-19 COVID-19

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements	NOTE 2. BASIS OF PRESENTATION, SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING PRONOUNCEMENTS Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q S-X. A description of the Company’s significant accounting policies is included in the Company’s annual report on Form 10-K. Other than as described below, there have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 28, 2022. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements, as well as the reported amounts of expenses during the reporting periods. These estimates and assumptions are based on the Company’s historical experience, and on various other factors that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Leases The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases right-of-use right-of-use right-of-use right-of-use ASC 842 provides practical expedients for an entity’s ongoing accounting. In calculating right-of-use assets and lease liabilities, the Company has elected to combine lease and non-lease components. Additionally, the Company has elected to apply the practical expedient related to short-term leases (i.e., leases having initial terms of 12 months or less at commencement date) as an accounting policy election. For short-term leases, the Company will not recognize a right-of-use asset or lease liability, but instead will recognize lease payments as an expense on a straight-line basis over the lease term. Recently Adopted Accounting Pronouncements ASC 842 requires lessees to recognize the liabilities related to all leases, including operating leases, with a term greater than 12 months on the balance sheet and also requires lessees and lessors to disclose key information about their leasing transactions. The Company adopted this guidance on January 1, 2022, using the modified retrospective method and the Company elected the package of practical expedients upon transition, which retained the lease classification for leases that existed prior to the adoption of this guidance. The Company recorded both a right-of-use In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes 2019-12”), 2019-12 Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

Marketable Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2022
Marketable Securities [Abstract]
Marketable Securities	NOTE 3. MARKETABLE SECURITIES Marketable securities consisted of the following as of March 31, 2022 and December 31, 2021 (in thousands): March 31, 2022 Amortized Cost Gross Unrealized Gross Unrealized Fair Value Available-for-sale Commercial paper $ 47,961 $ — $ — $ 47,961 Corporate debt securities 15,373 — (117 ) 15,256 Asset-backed securities 8,077 — (45 ) 8,032 U.S. treasury securities 9,093 — (16 ) 9,077 Total available-for-sale 80,505 — (178 ) 80,326 Available-for-sale Corporate debt securities 9,275 — (227 ) 9,048 Asset-backed securities 7,033 — (107 ) 6,926 U.S. treasury securities 11,985 — (302 ) 11,684 Total available-for-sale 28,294 — (636 ) 27,658 Total available-for-sale $ 108,798 $ — $ (814 ) $ 107,984 December 31, 2021 Amortized Cost Gross Unrealized Gross Unrealized Fair Value Available-for-sale Commercial paper $ 47,939 $ — $ — $ 47,939 Corporate debt securities 7,992 — (11 ) 7,981 Asset-backed securities 16,177 — (22 ) 16,155 Total available-for-sale 72,108 — (33 ) 72,075 Available-for-sale Corporate debt securities 16,816 — (103 ) 16,713 Asset-backed securities 3,013 — (25 ) 2,988 U.S. treasury securities 11,988 — (70 ) 11,918 Total available-for-sale 31,817 — (198 ) 31,619 Total available-for-sale $ 103,925 $ — $ (231 ) $ 103,694 As of March 31, 2022, the Company’s available-for-sale available-for-sale available-for-sale available-for-sale

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 4. FAIR VALUE MEASUREMENTS The Company’s financial assets and liabilities subject to fair value measurement on a recurring basis and the level of inputs used for such measurements were as follows (in thousands): Fair value measurements at reporting date using Quoted Prices in Significant Other Significant Fair Value at Assets included in: Cash and cash equivalents Money market securities $ 108,086 $ — $ — $ 108,086 Marketable securities Commercial paper — 47,961 — 47,961 Corporate debt securities — 24,304 — 24,304 Asset-backed securities — 14,958 — 14,958 U.S. treasury securities — 20,761 — 20,761 Total fair value $ 108,086 $ 107,984 $ — $ 216,070 Fair value measurements at reporting date using Quoted Prices in Significant Other Significant Fair Value at Assets included in: Cash and cash equivalents Money market securities $ 121,162 $ — $ — $ 121,162 Marketable securities Commercial paper — 47,939 — 47,939 Corporate debt securities — 24,694 — 24,694 Asset-backed securities — 19,143 — 19,143 U.S. treasury securities — 11,918 — 11,918 Total fair value $ 121,162 $ 103,694 $ — $ 224,856 The carrying values reported in the Company’s condensed balance sheets for cash (excluding cash equivalents which are recorded at fair value on a recurring basis), accounts payable and accrued expenses are reasonable estimates of their fair values due to the short-term nature of these items. The fair value of the Company’s money market funds is determined using quoted market prices in active markets for identical assets. The fair value for the available-for-sale

Supplemental Financial Informat

Supplemental Financial Information	3 Months Ended
	Mar. 31, 2022
Supplemental Financial Information [Abstract]
Supplemental Financial Information	NOTE 5. SUPPLEMENTAL FINANCIAL INFORMATION Prepaid expenses and other current assets consisted of the following (in thousands): March 31, 2022 December 31, 2021 Research and development service agreements $ 1,653 $ 2,591 Prepaid insurance 749 1,514 Dues and subscriptions 158 96 Prepaid raw materials 333 83 Other 115 140 Total prepaid expenses and other current assets $ 3,008 $ 4,424 Accrued expenses and other current liabilities consisted of the following (in thousands): March 31, 2022 December 31, 2021 Research and development $ 1,638 $ 2,623 Bonuses and other employee liabilities 541 1,102 Legal 294 130 Professional fees 6 — Other 99 204 Total accrued expenses and other current li a $ 2,578 $ 4,059

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Equity	NOTE 6. STOCKHOLDERS’ EQUITY Authorized Shares The total number of shares of all classes of capital stock authorized to be issued is 310,000,000, with 10,000,000 shares designated as preferred stock with a par value of $0.0001, and 300,000,000 shares designated as common stock with a par value of $0.0001. Common Stock As of March 31, 2022, the Company’s Amended and Restated Certificate of Incorporation authorized the issuance of 300,000,000 shares of common stock, $0.0001 par value per share. Each share of common stock is entitled to one voting right.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	NOTE 7 2021 Equity Incentive Plan The 2021 Equity Incentive Plan (the “2021 Plan”), which provides for the grant of incentive stock options to employees, and the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees, directors and consultants, became effective on June 30, 2021. The 2021 Plan is a successor to the Company’s Amended and Restated Stock Performance Plan that was adopted by the Board and stockholders on April 8, 2013 (as amended from time to time, most recently on November 20, 2020, the “2013 Plan”). Following the effectiveness of the 2021 Plan, no further grants may be made under the 2013 Plan; however, any outstanding equity awards granted under the 2013 Plan continue to be governed by the terms of the 2013 Plan. Initially, the maximum number of shares of the Company’s common stock that may be issued under the 2021 Plan was 7,698,282 shares, which is the sum of (1) 3,550,000 new shares, plus (2) 667,104 shares that remained available for issuance under the Company’s 2013 Plan at the time the 2021 Plan became effective, plus (3) any shares subject to outstanding stock options or other stock awards that were granted under the 2013 Plan that, on or after the 2021 Plan became effective, terminate or expire prior to exercise or settlement, are settled in cash, are forfeited or repurchased because of the failure to vest, or are reacquired or withheld to satisfy a tax withholding obligation or the purchase or exercise price in in accordance with the terms of the 2013 Plan. In addition, the number of shares of the Company’s common stock reserved for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to 5% of the total number of shares of the Company’s common stock outstanding on December 31 of the fiscal year before the date of each automatic increase, or a lesser number of shares determined by the Board prior to the applicable January 1. On January 1, 2022, the Board increased the number of shares of common stock reserved for issuance under the 2021 Plan by 2,023,663 shares. The maximum number of shares of the Company’s common stock that may be issued upon the exercise of incentive stock options under the 2021 Plan is 12,000,000. As of March 31, 2022, 9,721,945 shares were authorized for issuance under the 2021 Plan and 4,794,743 shares remained available for issuance under the 2021 Plan. Stock Options The Black-Scholes option-pricing model was used to estimate the fair value of stock options granted during the three months ended March 31, 2022 and 2021 with the following weighted average assumptions: Three Months Ended March 31, 2022 2021 Risk-free interest rate 1.71% 0.4% - 0.5% Expected term (in years) 6.1 5.3 - 6.1 Expected volatility 90% 90% Expected dividend yield 0% 0% The weighted average grant date fair value of options granted during the three months ended March 31, 2022 and 2021, was $3.87 per share and $0.57 per share, respectively. Prior to its IPO, the fair value of the Company’s common stock underlying the stock options has historically been determined by the Board with assistance from management and, occasionally with input from an independent third-party valuation firm. For the year ended December 31, 2020, management engaged an independent third-party valuation firm to provide an estimate of the fair value of its common stock, which was utilized as an input to the Company’s Black-Scholes option pricing model for stock options awarded during the three months ended March 31, 2021. Stock options granted after December 31, 2017 vest monthly over a range of to or vest monthly over a total of 48 months following a one-year cliff all ten-year three ten-year The following table reflects summarized stock option activity: Stock Options Weighted Average Weighted Average Aggregate Intrinsic Outstanding at December 31, 2021 3,835,618 $ 2.51 Granted 1,104,550 5.19 Forfeited (18,149 ) 1.19 Outstanding at March 31, 2022 4,922,019 $ 3.11 8.6 $ 9,562 Vested and exercisable at March 31, 2022 1,755,794 $ 1.54 7.5 $ 4,805 As of March 31, 2022, total unrecognized compensation costs related to unvested stock option awards granted was approximately $8.4 million, which the Company expects to recognize over a weighted-average period of approximately 3.1 years. The Company recorded stock-based compensation expense related to stock options in the following expense categories of its condensed statements of operations for the periods shown (in thousands): Three Months Ended March 31, 2022 2021 General and administrative $ 453 $ 79 Research and development 166 47 Total stock-based compensation $ 618 $ 126 Employee Stock Purchase Plan The 2021 Employee Stock Purchase Plan (the “ESPP”), which permits employees to purchase shares of the Company’s common stock, became effective on June 30, 2021. A total of 375,000 shares of the Company’s common stock were initially reserved for sale under the ESPP. The number of shares of the Company’s common stock reserved for issuance will automatically increase on January 1 of each calendar year, beginning on January 1, 2022 through January 1, 2031, by the lesser of (1) 1% of the total number of shares of the Company’s common stock outstanding on the last day of the fiscal year before the date of the automatic increase, and (2) 800,000 shares; provided that before the date of any such increase, the Board may determine that such increase will be less than the amount set forth in clauses (1) and (2). On January 1, 2022, the Board increased the number of shares of common stock reserved for issuance under the ESPP by 404,732 shares. As of March 31, 2022, there are 779,732 shares authorized for issuance under the ESPP and there have been no purchases of shares under the ESPP.

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	NOTE 8 The Company has been subleasing space in Indiana since March 1, 2020. The Company executed a new sublease for this space that was effective on February 1, 2021 and expires on August 30, 2023. The sublease does not provide the Company with any renewal options. The Company allows others to sublease a portion of the space from the Company for less than a one-year The following table summarizes quantitative information about the Company’s operating leases for the period indicated (in thousands): Three Months Ended Operating leases Operating lease cost $ 38 Less: sublease income (16 ) Operating lease expense 22 Short-term lease rent expense 5 Total rent expense $ 27 Supplemental information related to the Indiana lease was as follows (dollar amounts in thousands): Three Months Ended Operating cash flows from operating leases $ 38 Right-of-use $ 233 Weighted-average remaining lease term – operating leases 1.4 Weighted-average discount rate – operating leases 10.0 % As of March 31, 2022, the present value of maturities of the Company’s operating lease liabilities were as follows: Remaining Period Ended December 31, 2022 $ 115 Year Ended December 31, 2023 102 Total 217 Less: present value discount (16 ) Operating lease liabilities $ 201 The Company recognizes sublease income in other income, net on its condensed statements of operations and comprehensive loss. The Company expects to recognize approximately $16,000 in sublease income for the remainder of 2022. Prior to the adoption of ASC 842, and for the three months ended March 31, 2021, the Company recognized rent expense on a straight-line basis over the lease period and recorded deferred rent expense for rent expense incurred but not yet paid. During the three months ended March 31, 2021, the Company recognized total rent expense of approximately $27,000 and recognized sublease income of approximately $9,000. Disclosures related to periods prior to adoption of ASC 842 included approximate future minimum rental payments due under the Company’s leases as of December 31, 2021 as follows: Year ended December 31, 2022 $ 153 Year ended December 31, 2023 102 Total $ 255

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9 The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	NOTE 10 The Company computes loss per common share using the two-class The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per common share because to do so would be anti-dilutive: Three Months Ended March 31, 2022 2021 Shares issuable upon exercise of stock options 4,922,019 3,481,178 Shares issuable upon conversion of Series A Preferred Stock — 477,297 Shares issuable upon conversion of Series A-1 — 7,537,879 Shares issuable upon conversion of Series B Preferred Stock — 11,862,043 Shares issuable upon exercise of common stock warrants — 385,693 Shares issuable upon exercise of preferred stock warrant — 447,426 Total 4,922,019 24,191,516

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q S-X. A description of the Company’s significant accounting policies is included in the Company’s annual report on Form 10-K. Other than as described below, there have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 28, 2022.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements, as well as the reported amounts of expenses during the reporting periods. These estimates and assumptions are based on the Company’s historical experience, and on various other factors that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Leases	Leases The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases right-of-use right-of-use right-of-use right-of-use ASC 842 provides practical expedients for an entity’s ongoing accounting. In calculating right-of-use assets and lease liabilities, the Company has elected to combine lease and non-lease components. Additionally, the Company has elected to apply the practical expedient related to short-term leases (i.e., leases having initial terms of 12 months or less at commencement date) as an accounting policy election. For short-term leases, the Company will not recognize a right-of-use asset or lease liability, but instead will recognize lease payments as an expense on a straight-line basis over the lease term.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements ASC 842 requires lessees to recognize the liabilities related to all leases, including operating leases, with a term greater than 12 months on the balance sheet and also requires lessees and lessors to disclose key information about their leasing transactions. The Company adopted this guidance on January 1, 2022, using the modified retrospective method and the Company elected the package of practical expedients upon transition, which retained the lease classification for leases that existed prior to the adoption of this guidance. The Company recorded both a right-of-use In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes 2019-12”), 2019-12
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2022
Marketable Securities [Abstract]
Summary of Marketable securities	Marketable securities consisted of the following as of March 31, 2022 and December 31, 2021 (in thousands): March 31, 2022 Amortized Cost Gross Unrealized Gross Unrealized Fair Value Available-for-sale Commercial paper $ 47,961 $ — $ — $ 47,961 Corporate debt securities 15,373 — (117 ) 15,256 Asset-backed securities 8,077 — (45 ) 8,032 U.S. treasury securities 9,093 — (16 ) 9,077 Total available-for-sale 80,505 — (178 ) 80,326 Available-for-sale Corporate debt securities 9,275 — (227 ) 9,048 Asset-backed securities 7,033 — (107 ) 6,926 U.S. treasury securities 11,985 — (302 ) 11,684 Total available-for-sale 28,294 — (636 ) 27,658 Total available-for-sale $ 108,798 $ — $ (814 ) $ 107,984 December 31, 2021 Amortized Cost Gross Unrealized Gross Unrealized Fair Value Available-for-sale Commercial paper $ 47,939 $ — $ — $ 47,939 Corporate debt securities 7,992 — (11 ) 7,981 Asset-backed securities 16,177 — (22 ) 16,155 Total available-for-sale 72,108 — (33 ) 72,075 Available-for-sale Corporate debt securities 16,816 — (103 ) 16,713 Asset-backed securities 3,013 — (25 ) 2,988 U.S. treasury securities 11,988 — (70 ) 11,918 Total available-for-sale 31,817 — (198 ) 31,619 Total available-for-sale $ 103,925 $ — $ (231 ) $ 103,694

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The Company’s financial assets and liabilities subject to fair value measurement on a recurring basis and the level of inputs used for such measurements were as follows (in thousands): Fair value measurements at reporting date using Quoted Prices in Significant Other Significant Fair Value at Assets included in: Cash and cash equivalents Money market securities $ 108,086 $ — $ — $ 108,086 Marketable securities Commercial paper — 47,961 — 47,961 Corporate debt securities — 24,304 — 24,304 Asset-backed securities — 14,958 — 14,958 U.S. treasury securities — 20,761 — 20,761 Total fair value $ 108,086 $ 107,984 $ — $ 216,070 Fair value measurements at reporting date using Quoted Prices in Significant Other Significant Fair Value at Assets included in: Cash and cash equivalents Money market securities $ 121,162 $ — $ — $ 121,162 Marketable securities Commercial paper — 47,939 — 47,939 Corporate debt securities — 24,694 — 24,694 Asset-backed securities — 19,143 — 19,143 U.S. treasury securities — 11,918 — 11,918 Total fair value $ 121,162 $ 103,694 $ — $ 224,856

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	3 Months Ended
	Mar. 31, 2022
Supplemental Financial Information [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): March 31, 2022 December 31, 2021 Research and development service agreements $ 1,653 $ 2,591 Prepaid insurance 749 1,514 Dues and subscriptions 158 96 Prepaid raw materials 333 83 Other 115 140 Total prepaid expenses and other current assets $ 3,008 $ 4,424
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following (in thousands): March 31, 2022 December 31, 2021 Research and development $ 1,638 $ 2,623 Bonuses and other employee liabilities 541 1,102 Legal 294 130 Professional fees 6 — Other 99 204 Total accrued expenses and other current li a $ 2,578 $ 4,059

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Assumptions Used for Valuation of Fair Value of Stock Options	The Black-Scholes option-pricing model was used to estimate the fair value of stock options granted during the three months ended March 31, 2022 and 2021 with the following weighted average assumptions: Three Months Ended March 31, 2022 2021 Risk-free interest rate 1.71% 0.4% - 0.5% Expected term (in years) 6.1 5.3 - 6.1 Expected volatility 90% 90% Expected dividend yield 0% 0%
Summary of Stock Option Activity	The following table reflects summarized stock option activity: Stock Options Weighted Average Weighted Average Aggregate Intrinsic Outstanding at December 31, 2021 3,835,618 $ 2.51 Granted 1,104,550 5.19 Forfeited (18,149 ) 1.19 Outstanding at March 31, 2022 4,922,019 $ 3.11 8.6 $ 9,562 Vested and exercisable at March 31, 2022 1,755,794 $ 1.54 7.5 $ 4,805
Summary of Share-Based Compensation Expense Related to Stock Options	The Company recorded stock-based compensation expense related to stock options in the following expense categories of its condensed statements of operations for the periods shown (in thousands): Three Months Ended March 31, 2022 2021 General and administrative $ 453 $ 79 Research and development 166 47 Total stock-based compensation $ 618 $ 126

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Summary of Lease, Cost	The following table summarizes quantitative information about the Company’s operating leases for the period indicated (in thousands): Three Months Ended Operating leases Operating lease cost $ 38 Less: sublease income (16 ) Operating lease expense 22 Short-term lease rent expense 5 Total rent expense $ 27
Schedule Of Supplemental Information Related To Lease	Supplemental information related to the Indiana lease was as follows (dollar amounts in thousands): Three Months Ended Operating cash flows from operating leases $ 38 Right-of-use $ 233 Weighted-average remaining lease term – operating leases 1.4 Weighted-average discount rate – operating leases 10.0 %
Summary of Lessee, Operating Lease, Liability, Maturity	As of March 31, 2022, the present value of maturities of the Company’s operating lease liabilities were as follows: Remaining Period Ended December 31, 2022 $ 115 Year Ended December 31, 2023 102 Total 217 Less: present value discount (16 ) Operating lease liabilities $ 201
Schedule of Future Minimum Rental Payments for Operating Leases	Disclosures related to periods prior to adoption of ASC 842 included approximate future minimum rental payments due under the Company’s leases as of December 31, 2021 as follows: Year ended December 31, 2022 $ 153 Year ended December 31, 2023 102 Total $ 255

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Summary of Dilutive Securities Not Included in the Diluted Net Loss Per Common Share	The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per common share because to do so would be anti-dilutive: Three Months Ended March 31, 2022 2021 Shares issuable upon exercise of stock options 4,922,019 3,481,178 Shares issuable upon conversion of Series A Preferred Stock — 477,297 Shares issuable upon conversion of Series A-1 — 7,537,879 Shares issuable upon conversion of Series B Preferred Stock — 11,862,043 Shares issuable upon exercise of common stock warrants — 385,693 Shares issuable upon exercise of preferred stock warrant — 447,426 Total 4,922,019 24,191,516

Description of Organization a_2

Description of Organization and Business Operations - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jul. 08, 2021	Jul. 06, 2021	Jun. 23, 2021	Mar. 31, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stockholders' equity, reverse stock split			1-for-1.49
Conversion of stock, shares converted		477,297
Accumulated deficit				$ (136,700)	$ (127,571)
Working capital				$ 188,100	$ 193,500
Total number of outstanding shares increased		39,911,517
Common Stock Warrants [Member] | Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of securities called by warrants or rights		178,847
Series A-1 Convertible Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Conversion of stock, shares converted		7,985,305
Series B Convertible Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Conversion of stock, shares converted		19,770,070
IPO [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock, number of shares issued in transaction		9,999,999
Underwriting shares	1,499,999
Sale of stock, price per share		$ 16
Sale of stock, consideration received on transaction		$ 168,600
underwriting discounts and commissions and other offering expenses		$ 15,400

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Jan. 01, 2022
Right-of-use asset	$ 201	$ 200
Lease liability	$ 201	$ 200

Marketable Securities - Additio

Marketable Securities - Additional Information (Details) - Marketable Debt Securities [Member] - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2022
Marketable Securities [Line Items]
Available-for-sale securities classified as short-term maturity	one year or less
Available-for-sale securities classified as long-term maturity	two years
Other than temporary impairment losses, investments portion in other comprehensive loss net of tax available-for sale securities		$ 0

Marketable Securities - Summary

Marketable Securities - Summary of Marketable securities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Marketable Debt Securities Short Term [Member]
Marketable Securities [Line Items]
Amortized cost, Short term	$ 80,505	$ 72,108
Gross Unrealized Loss	(178)	(33)
Fair value, Short Term	80,326	72,075
Marketable Debt Securities Long Term [Member]
Marketable Securities [Line Items]
Gross Unrealized Loss	(636)	(198)
Amortized cost, Long term	28,294	31,817
Fair value, Long Term	27,658	31,619
Marketable Debt Securities [Member]
Marketable Securities [Line Items]
Gross Unrealized Loss	(814)	(231)
Amortized Cost, Total	108,798	103,925
Fair value, Total	107,984	103,694
Commercial Paper [Member] | Marketable Debt Securities Short Term [Member]
Marketable Securities [Line Items]
Amortized cost, Short term	47,961	47,939
Fair value, Short Term	47,961	47,939
Corporate Debt Securities [Member] | Marketable Debt Securities Short Term [Member]
Marketable Securities [Line Items]
Amortized cost, Short term	15,373	7,992
Gross Unrealized Loss	(117)	(11)
Fair value, Short Term	15,256	7,981
Corporate Debt Securities [Member] | Marketable Debt Securities Long Term [Member]
Marketable Securities [Line Items]
Gross Unrealized Loss	(227)	(103)
Amortized cost, Long term	9,275	16,816
Fair value, Long Term	9,048	16,713
Asset-backed Securities [Member] | Marketable Debt Securities Short Term [Member]
Marketable Securities [Line Items]
Amortized cost, Short term	8,077	16,177
Gross Unrealized Loss	(45)	(22)
Fair value, Short Term	8,032	16,155
Asset-backed Securities [Member] | Marketable Debt Securities Long Term [Member]
Marketable Securities [Line Items]
Gross Unrealized Loss	(107)	(25)
Amortized cost, Long term	7,033	3,013
Fair value, Long Term	6,926	2,988
US Treasury Securities [Member] | Marketable Debt Securities Short Term [Member]
Marketable Securities [Line Items]
Amortized cost, Short term	9,093
Gross Unrealized Loss	(16)
Fair value, Short Term	9,077
US Treasury Securities [Member] | Marketable Debt Securities Long Term [Member]
Marketable Securities [Line Items]
Gross Unrealized Loss	(302)	(70)
Fair value, Short Term	11,684
Amortized cost, Long term	$ 11,985	11,988
Fair value, Long Term		$ 11,918

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Marketable securities
Total fair value	$ 216,070	$ 224,856
Fair Value, Inputs, Level 1 [Member]
Marketable securities
Total fair value	108,086	121,162
Fair Value, Inputs, Level 2 [Member]
Marketable securities
Total fair value	107,984	103,694
Fair Value, Inputs, Level 3 [Member]
Marketable securities
Total fair value	0	0
Money Market Securities [Member]
Cash and cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure	108,086	121,162
Money Market Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure	108,086	121,162
Money Market Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Money Market Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Commercial Paper [Member]
Marketable securities
Investments, Fair Value Disclosure	47,961	47,939
Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]
Marketable securities
Investments, Fair Value Disclosure	0
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Marketable securities
Investments, Fair Value Disclosure	47,961	47,939
Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]
Marketable securities
Investments, Fair Value Disclosure	0
Corporate Debt Securities [Member]
Marketable securities
Investments, Fair Value Disclosure	24,304	24,694
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Marketable securities
Investments, Fair Value Disclosure	0
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Marketable securities
Investments, Fair Value Disclosure	24,304	24,694
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Marketable securities
Investments, Fair Value Disclosure	0
Asset-backed Securities [Member]
Marketable securities
Investments, Fair Value Disclosure	14,958	19,143
Asset-backed Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Marketable securities
Investments, Fair Value Disclosure	0
Asset-backed Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Marketable securities
Investments, Fair Value Disclosure	14,958	19,143
Asset-backed Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Marketable securities
Investments, Fair Value Disclosure	0
US Treasury Securities [Member]
Marketable securities
Investments, Fair Value Disclosure	20,761	11,918
US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Marketable securities
Investments, Fair Value Disclosure	0
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Marketable securities
Investments, Fair Value Disclosure	20,761	$ 11,918
US Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Marketable securities
Investments, Fair Value Disclosure	$ 0

Supplemental Financial Inform_3

Supplemental Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Disclosure Of Prepaid Expenses And Other Current Assets [Line Items]
Research and development service agreements	$ 1,653	$ 2,591
Prepaid Insurance	749	1,514
Dues and subscriptions	158	96
Prepaid raw materials	333	83
Other	115	140
Total prepaid expenses and other current assets	$ 3,008	$ 4,424

Supplemental Financial Inform_4

Supplemental Financial Information - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Disclosure of Accrued Expenses and Other Current Liabilities [Line Items]
Research and development	$ 1,638	$ 2,623
Bonuses and other employee liabilities	541	1,102
Legal	294	130
Professional fees	6
Other	99	204
Total accrued expenses and other current liabilities	$ 2,578	$ 4,059

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Common stock shares authorized	300,000,000	300,000,000
Common stock par or stated value per share	$ 0.0001	$ 0.0001
Common stock shares voting rights	one
Preferred stock, shares authorized	10,000,000	10,000,000
Total shares authorized	310,000,000
Preferred stock, par or stated value per share	$ 0.0001	$ 0.0001

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jan. 01, 2022	Dec. 31, 2021	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting period	48 months
Share based compensation by share based payment arrangement contractual term	10 years
Share based compensation by share based payment arrangement unrecognized compensation costs non vested options	$ 8.4
Share based compensation by share based payment arrangement unrecognized compensation costs weighted aveage period of recognition	3 years 1 month 6 days
Weighted average grant date fair value of options granted	$ 3.87	$ 0.57
Common stock shares authorized	300,000,000			300,000,000
Stock Options Granted Before December 31, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation by share based payment arrangement contractual term	10 years
2013 Amended And Restated Stock Performance Plan [Member] | Stock Options Granted Before December 31, 2017 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting period	3 months
2013 Amended And Restated Stock Performance Plan [Member] | Stock Options Granted Before December 31, 2017 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting period	24 months
2021 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant	4,794,743				7,698,282
Share based compensation arrangement by share based payment award Cumulative annual increase in common stock shares reserved for issuance, percentage					5.00%
Share based compensation arrangement by share based payment award number of shares authorized	9,721,945
2021 Equity Incentive Plan [Member] | New Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant					3,550,000
2021 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum threshold common stock issuable on exercise of incentive stock options					12,000,000
Common stock, capital shares reserved for future issuance			2,023,663
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance			404,732
Share based compensation arrangement by share based payment award Cumulative annual increase in shares reserved for issuance, percentage					1.00%
Share based compensation arrangement by share based payment award shares of common stock outstanding maximum cumulative annual increase					800,000
Stock issued during period shares employee stock purchase plans	0
Common stock shares authorized	779,732
Employee Stock Purchase Plan [Member] | Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance					375,000
Two Thousand And Thirteen Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant					667,104
2013 and 2021 Equity Incentive Plan [Member] | Stock Options Granted After December 31, 2017 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting period	12 months
2013 and 2021 Equity Incentive Plan [Member] | Stock Options Granted After December 31, 2017 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting period	36 months

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Assumptions Used for Valuation of Fair Value of Stock (Detail) - Black-Scholes Option-Pricing Model [Member]	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Risk-free interest rate	1.71%
Expected term in years	6 years 1 month 6 days
Expected volatility	90.00%	90.00%
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Risk-free interest rate, minimum		0.40%
Expected term in years		5 years 3 months 18 days
Maximum [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Risk-free interest rate, maximum		0.50%
Expected term in years		6 years 1 month 6 days

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Option Activity (Detail) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance, Stock Options | shares	3,835,618
Stock options granted, Stock Options | shares	1,104,550
Stock options forfeited, Stock Options | shares	(18,149)
Ending balance, Stock Options | shares	4,922,019
Vested and exercisable, Stock Options | shares	1,755,794
Beginning balance, Weighted Average Exercise Price | $ / shares	$ 2.51
Options granted, Weighted Average Exercise Price | $ / shares	5.19
Options Forfeited, Weighted Average Exercise Price | $ / shares	1.19
Ending balance, Weighted Average Exercise Price | $ / shares	3.11
Vested and exercisable, Weighted Average Exercise Price | $ / shares	$ 1.54
Weighted Average Remaining Contractual Life (in years)	8 years 7 months 6 days
Vested and exercisable, Weighted Average Remaining Contractual Life (in years)	7 years 6 months
Ending balance, Aggregate Intrinsic Value | $	$ 9,562
Vested and exercisable, Aggregate Intrinsic Value | $	$ 4,805

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Share-Based Compensation Expense Related to Stock Options (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 618	$ 126
General and Administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	453	79
Research and Development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 166	$ 47

Leases - Summary of Lease, Cost

Leases - Summary of Lease, Cost (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating leases
Operating lease cost	$ 38,000
Less: sublease income	(16,000)	$ (9,000)
Operating lease expense	22,000
Short-term lease rent expense	5,000
Total rent expense	$ 27,000	$ 27,000

Leases - Schedule Of Supplement

Leases - Schedule Of Supplemental Information Related To Lease (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Leases [Abstract]
Operating cash flows from operating leases	$ 38
Right-of-use assets obtained in exchange for operating lease liabilities	$ 233
Weighted-average remaining lease term – operating leases	1 year 4 months 24 days
Weighted-average discount rate – operating leases	10.00%

Leases - Summary of Lessee, Op

Leases - Summary of Lessee, Operating Lease, Liability, Maturity (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Jan. 01, 2022
Leases [Abstract]
Remaining Period Ended December 31, 2022	$ 115
Year Ended December 31, 2023	102
Total	217
Less: present value discount	(16)
Operating lease liabilities	$ 201	$ 200

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail) $ in Thousands	Dec. 31, 2021USD ($)
Leases [Abstract]
Year ended December 31, 2022	$ 153
Year ended December 31, 2023	102
Total	$ 255

Lease - Additional Information

Lease - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Sublease income for the remainder of 2022	$ 16,000
Sublease income	16,000	$ 9,000
Rent expense	$ 27,000	$ 27,000

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Dilutive Securities Not Included in the Diluted Net Loss Per Common Share (Detail) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Conversion of stock, shares converted	4,922,019	24,191,516
Exercise of Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Conversion of stock, shares converted	4,922,019	3,481,178
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Conversion of stock, shares converted	0	477,297
Series A1 Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Conversion of stock, shares converted	0	7,537,879
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Conversion of stock, shares converted	0	11,862,043
Common stock warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Conversion of stock, shares converted	0	385,693
Preferred stock warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Conversion of stock, shares converted	0	447,426